Skip to main content
SpringerLink
Log in

Measles–Mumps–Rubella–Varicella Combination Vaccine (ProQuad®): A Guide to Its Use in Children in the EU

  • Adis Drug Clinical Q&A
  • Published:
Pediatric Drugs Aims and scope Submit manuscript

Abstract

In the EU, the live attenuated, tetravalent measles–mumps–rubella–varicella vaccine ProQuad® is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age using a two-dose schedule and may be used in infants from 9 months of age to conform with a national vaccination schedule, outbreak situations or travel to a region with a high prevalence of measles. Clinical data in young children indicates that vaccination with ProQuad® is as immunogenic as the component vaccines, provides long-term protection against these potentially serious childhood infections and has an acceptable safety profile. Combining the viral strains of the measles–mumps–rubella vaccine M–M–RVAXPRO® and the varicella vaccine Varivax® in ProQuad® reduces the complexity of vaccination schedules, thereby potentially improving vaccination coverage and the timeliness of vaccination.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. WHO, UNICEF, World Bank. State of the world’s vaccines and immunization, 3rd ed. Geneva: World Health Organization; 2009.

  2. World Health Organization. European vaccine action plan 2015–2020. 2014. http://www.euro.who.int. Accessed 22 Dec 2014.

  3. Haverkate M, D’Ancona F, Giambi C, et al. Mandatory and recommended vaccination in the EU, Iceland and Norway: results of the VENICE 2012 survey on ways of implementing national vaccination programmes. Euro Surveill. 2012;17(22):20183.

    PubMed  Google Scholar 

  4. European Centre for Disease Prevention and Control. ECDC technical report. Measles and rubella elimination: communicating the importance of vaccination. 2014. http://ecdc.europa.eu. Accessed 2 Feb 2015.

  5. European Centre for Disease Prevention and Control. ECDC preliminary guidance: varicella vaccine in the European Union. 2014. http://www.ecdc.europa.eu. Accessed 2 Feb 2015.

  6. Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committees on Immunization Practices (ACIP). 2007. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5604a1.htm. Accessed 16 Feb 2015.

  7. Vesikari T, Sadzot-Delvaux C, Rentier B, et al. Increasing coverage and efficiency for measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for a combined vaccine. Pediatr Infect Dis J. 2007;26(7):632–8.

    Article  PubMed  Google Scholar 

  8. Ramet J. A new challenge for Europe: introducing a pediatric quadrivalent vaccine for measles, mumps, rubella, and varicella. Int J Infect Dis. 2007;11(Suppl 2):S49–55.

    Article  PubMed  Google Scholar 

  9. World Health Organization. WHO recommendations for routine immunization—summary tables. 2012. http://www.who.int/immunization/policy/immunization_tables/en/. Accessed 8 Dec 2012.

  10. Ackerson BK, Sy LS, Cheetham TC, et al. Impact of MMRV combination vaccine on childhood vaccination compliance. Am J Manag Care. 2012;18(12):e440–5.

    PubMed  Google Scholar 

  11. European Medicines Agency. Summary of product characteristics: ProQuad powder and solvent for suspension for injection. 2011. http://www.ema.europa.eu. Accessed 16 Dec 2014.

  12. Vesikari T, Becker T, Gajdos V, et al. Immunogenicity and safety of a two-dose regimen of a combined measles, mumps, rubella and varicella live vaccine (ProQuad®) in infants from 9 months of age. Vaccine. 2012;30(20):3082–9.

    Article  CAS  PubMed  Google Scholar 

  13. Shinefield H, Black S, Williams WR, et al. Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):670–5.

    Article  PubMed  Google Scholar 

  14. Shinefield H, Black S, Digilio L, et al. Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Pediatr Infect Dis J. 2005;24(8):665–9.

    Article  PubMed  Google Scholar 

  15. Lieberman JM, Williams WR, Miller JM, et al. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006;25(7):615–22.

    Article  PubMed  Google Scholar 

  16. Shinefield H, Black S, Thear M, et al. Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines. Pediatr Infect Dis J. 2006;25(4):287–92.

    Article  PubMed  Google Scholar 

  17. Reisinger KS, Brown ML, Xu J, et al. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M–M–RII and Varivax. Pediatrics. 2006;117(2):265–72.

    Article  PubMed  Google Scholar 

  18. Kuter BJ, Brown ML, Hartzel J, et al. Safety and immunogenicity of a combination measles, mumps, rubella and varicella vaccine (ProQuad®). Hum Vaccin. 2006;2(5):205–14.

    Article  CAS  PubMed  Google Scholar 

  19. Bernstein HH, Eves K, Campbell K, et al. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live). Pediatrics. 2007;119(6):e1299–305.

    Article  PubMed  Google Scholar 

  20. Yetman RJ, Shepard JS, Duke A, et al. Concomitant administration of hepatitis A vaccine with measles/mumps/rubella/varicella and pneumococcal vaccines in healthy 12- to 23-month-old children. Hum Vaccin Immunother. 2013;9(8):1691–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Leonardi M, Bromberg K, Baxter R, et al. Immunogenicity and safety of MMRV and PCV-7 administered concomitantly in healthy children. Pediatrics. 2011;128(6):e1387–94.

    Article  PubMed  Google Scholar 

  22. Blatter MM, Klein NP, Shepard JS, et al. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis A and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012;31(8):e133–40.

    Article  PubMed  Google Scholar 

  23. Klein NP, Shepard J, Bedell L, et al. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012;30(26):3929–36.

    Article  CAS  PubMed  Google Scholar 

  24. Klopfer SO, Stek JE, Petrecz M, et al. Analysis of safety data in children after receiving two doses of ProQuad® (MMRV). Vaccine. 2014;32(52):7154–60.

    Article  PubMed  Google Scholar 

  25. Schink T, Holstiege J, Kowalzik F, et al. Risk of febrile convulsions after MMRV vaccination in comparison to MMR or MMR+V vaccination. Vaccine. 2014;32(6):645–50.

    Article  CAS  PubMed  Google Scholar 

  26. Klein NP, Fireman B, Yih WK, et al. Measles–mumps–rubella–varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010;126(1):e1–8.

    Article  PubMed  Google Scholar 

  27. Klein NP, Lewis E, Baxter R, et al. Measles–containing vaccines and febrile seizures in children age 4 to 6 years. Pediatrics. 2012;129(5):809–14.

    Article  PubMed  Google Scholar 

  28. Jacobsen SJ, Ackerson BK, Sy LS, et al. Observational safety study of febrile convulsion following first dose MMRV vaccination in a managed care setting. Vaccine. 2009;27(34):4656–61.

    Article  PubMed  Google Scholar 

  29. MacDonald SE, Dover DC, Simmonds KA, et al. Risk of febrile seizures after first dose of measles–mumps–rubella–varicella vaccine: a population-based cohort study. CMAJ. 2014;186(11):824–9.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Disclosure

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author the basis of scientific and editorial merit. Lesley J. Scott is a salaried employee of Adis/Springer.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Lesley J. Scott

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Additional information

The manuscript was reviewed by: S. Saluja, Saran Ashram Hospital, Dayalbagh, Agar, India; M. Petras, Charles University of Prague, 2nd Faculty of Medicine, Preventive Medicine, Prague, Czech Republic.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Scott, L.J. Measles–Mumps–Rubella–Varicella Combination Vaccine (ProQuad®): A Guide to Its Use in Children in the EU. Pediatr Drugs 17, 167–174 (2015). https://doi.org/10.1007/s40272-015-0123-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40272-015-0123-7

Keywords

Search

Navigation